Artificial Intelligence | Machine Learning | Natural Language Processing Insilico Medicine | Drug Discovery & Development


Enterprise, Health Care, Pharmaceutical & Medical Products, Drug Discovery, Digital Medicine Pak Shek Kok, Hong Kong

Insilico Medicine

Artificial Intelligence | Machine Learning | Natural Language Processing


Insilico Medicine | Drug Discovery & Development

Insilico Medicine

Health Care, Pharmaceutical & Medical Products, Drug Discovery, Digital Medicine


Pak Shek Kok, Hong Kong

Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in the USA, Belgium, Russia, UK, Taiwan, and China sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research. Insilico Medicine pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief.

 

B2B

51 to 100

Series D

$401.3M

Scaling Up

2014

 
 

Pharmaceuticals and Medical Products
Healthcare
Health Care Facilities & Hospitals

Increasing Probabilities of success
Decreasing Costs of Medicine
AI Scoring & Analysis

Increase Efficiency

 
 

Production

Yes

Active

 
 

   Machine Learning
   Natural Language Processing


Drug Discovery

Drug Discovery


Image

Image

Video

Video

Text

Text

Structured

Structured

 

   Software


Python

Python

.Net

.Net

AWS Redshift

AWS Redshift

Airflow

Airflow

Angular.js

Angular.js

Azure

Azure

SQL

SQL


Machine Learning Algorithm

Machine Learning Algorithm

Deep Learning Algorithm

Deep Learning Algorithm

 
 

View All

View All AI/ML Jobs

Machine Learning Engineer

Shanghai , Pudong

Machine Learning Research Scientist

Shanghai , Pudong

PandaOmics Global Product Manager

Business Development Consultant

Remote, Remote

Sales Development Representative

Shanghai , Pudong

 

AI/ML Professionals

Want to work at Insilico Medicine?

We can introduce you to the right person at Insilico Medicine

Talk to our Talent Team

 

20

3

$116.67M

Company was founded 2014 and it took almost 7 years (Jun 2021) to raise first external round

 
 

Date

Round

$ Raised

Investors

08/10/2022

Series D

$35M

Prosperity7 Ventures

Date : 08/10/2022

Round: Series D

$ Raised: $35M

Investors: Prosperity7 Ventures

06/06/2022

Series D

$60M

BHR Partners, Warburg Pincus, B Capital Group, Qiming Venture Partners, Bold Capital Partners, Pavilion Capital

Date : 06/06/2022

Round: Series D

$ Raised: $60M

Investors: BHR Partners, Warburg Pincus, B Capital Group, Qiming Venture Partners, Bold Capital Partners, Pavilion Capital

06/22/2021

Series C

$255M

B Capital Group, Bold Capital Partners, Baidu Ventures, CPE, Deerfield, Eight Road Ventures, Michael Antonov, Lake Bleu Capital, Lilly Asia Ventures, Maison Capital, OrbiMed, Pavilion Capital, President International Development Corporation, Qiming Venture Partners, Sage Partners, Sequoia Capital India, Sinovation Ventures, Warburg Pincus

Date : 06/22/2021

Round: Series C

$ Raised: $255M

Investors: B Capital Group, Bold Capital Partners, Baidu Ventures, CPE, Deerfield, Eight Road Ventures, Michael Antonov, Lake Bleu Capital, Lilly Asia Ventures, Maison Capital, OrbiMed, Pavilion Capital, President International Development Corporation, Qiming Venture Partners, Sage Partners, Sequoia Capital India, Sinovation Ventures, Warburg Pincus

 

Investors

Interested in researching Insilico Medicine?

We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Insilico Medicine

Request a Demo - Deal Souring Platform

 
Qingsong Zhu


Qingsong Zhu
COO

Alex Zhavoronkov


Alex Zhavoronkov
Founder and CEO

Alex Zhebrak


Alex Zhebrak
CTO

Feng Ren


Feng Ren
CSO

Alex Aliper

Alex Aliper
President

Nirav Jhaveri

Nirav Jhaveri
Chief Financial Officer

Michelle Chen

Michelle Chen
Chief Business Officer

 
 

Potential Customers

Interested in what they do or partnership?

Learn more about how they work

Schedule a Call w/ Insilico Medicine